Financials data is unavailable for this security.
View more
Year on year Silence Therapeutics PLC had net income fall 6.86% from a loss of 40.49m to a larger loss of 43.27m despite a 44.99% increase in revenues from 17.50m to 25.38m.
| Gross margin | 56.40% |
|---|---|
| Net profit margin | -224.01% |
| Operating margin | -270.81% |
| Return on assets | -28.51% |
|---|---|
| Return on equity | -64.28% |
| Return on investment | -32.89% |
More ▼
Cash flow in GBPView more
In 2023, Silence Therapeutics PLC did not generate a significant amount of cash. Cash Flow from Financing totalled 25.16m or 99.13% of revenues. In addition the company used 39.35m for operations while cash from investing totalled 16.43m.
| Cash flow per share | -1.21 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 3.06 |
|---|---|
| Tangible book value per share | 2.85 |
More ▼
Balance sheet in GBPView more
| Current ratio | 9.83 |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | 0.0016 |
|---|---|
| Total debt/total capital | 0.0016 |
More ▼
